HealthManagement
Promoting Management and Leadership

How to Enhance Brain Imaging with [18F]FDG PET



Brain imaging is critical in diagnosing neurological, psychiatric and neuro-oncological disorders. Among the techniques available, 2-[^{18}F]fluoro-2-deoxy-D-glucose ([^{18}F]FDG) PET imaging stands out for its ability to map regional glucose metabolism, which is a key indicator of neuronal activity. The updated guidelines by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) emphasise best practices and technological advancements in [^{18}F]FDG PET imaging. These recommendations aim to improve the accuracy of diagnoses and enhance patient outcomes through consistent and high-quality standards.

Technological Advancements in PET Imaging

Recent advances in PET technology, such as digital PET, hybrid PET/MR systems and brain-dedicated PET systems, have significantly improved the sensitivity and accuracy of imaging. These systems allow for better detection of metabolic abnormalities that often precede structural changes visible through traditional modalities like CT or MRI. For instance, hybrid PET/MR systems integrate functional and anatomical data, giving clinicians a more comprehensive view of brain activity and potential abnormalities. This is especially important in diagnosing neurodegenerative diseases, where early detection is crucial. The guidelines advocate incorporating these newer technologies into clinical practice wherever possible, particularly when investigating conditions like Alzheimer's disease (AD) and Parkinsonian syndromes.

Additionally, the document highlights the increasing use of digital PET and large axial field-of-view systems that offer better spatial resolution and enable dynamic imaging. Digital PET technology improves the quantification of glucose metabolism, making it possible to detect subtle changes that may signal the onset of neurodegenerative diseases. Such innovations are invaluable for identifying atypical presentations of diseases, like the visual variant of AD or primary progressive aphasia. This integration of newer technologies aims to elevate the diagnostic impact of [^{18}F]FDG PET in clinical and research settings.

Key Clinical Applications and Indications

[18F]FDG PET is used in various clinical scenarios, including neurodegenerative disorders, epilepsy, movement disorders, and neuro-oncology. The updated guidelines outline its crucial role in differential diagnosis, early detection and treatment planning.

In cases of cognitive impairment and dementia, [^{18}F]FDG PET imaging is instrumental in differentiating AD from other forms of dementia, such as frontotemporal lobar degeneration (FTLD) and dementia with Lewy bodies (DLB). The guidelines emphasise that [18F]FDG PET should be integrated with other biomarkers, like amyloid PET and cerebrospinal fluid (CSF) markers, for a more comprehensive diagnostic approach. The characteristic hypometabolic patterns seen in [18F]FDG PET imaging, such as posterior cortical hypometabolism in AD or frontotemporal hypometabolism in FTLD, can guide the diagnostic process when other clinical and imaging data are inconclusive.

For movement disorders, particularly Parkinsonian syndromes, [^{18}F]FDG PET helps distinguish idiopathic Parkinson's disease (PD) from atypical parkinsonism, such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). In these cases, characteristic metabolic patterns—such as basal ganglia hypermetabolism in PD or subcortical hypometabolism in PSP—provide critical information for accurate diagnosis. This allows for earlier and more precise treatment strategies.

In epilepsy, [^{18}F]FDG PET imaging is a valuable tool for presurgical evaluations of focal epilepsy. It helps identify the epileptogenic zone, particularly in cases where MRI findings are ambiguous or negative. This imaging modality is particularly sensitive in temporal lobe epilepsy, correlating well with clinical symptoms and supporting surgical planning.

In neuro-oncology, the guidelines recognise the utility of [18F]FDG PET in evaluating primary central nervous system lymphomas (PCNSL) and distinguishing between tumour recurrence and radiation necrosis. The high metabolic activity of PCNSL lesions is clearly delineated on [18F]FDG PET images, aiding in treatment decisions. Although amino-acid PET imaging may be superior in some glioma cases, [18F]FDG PET remains a viable option when alternative tracers are unavailable.

Best Practices for PET Imaging: Patient Preparation and Image Acquisition

The updated guidelines stress the importance of thorough patient preparation and strict adherence to procedural protocols. Proper preparation minimises potential sources of error and enhances the accuracy of the results.

Patient Preparation: Patients should fast for 4 to 6 hours before the scan to stabilise blood glucose levels. High blood glucose can interfere with [18F]FDG uptake, leading to poor image contrast between grey and white matter. Patients are encouraged to drink water to stay hydrated, and any intravenous fluids containing dextrose should be withheld. Specific patient groups, like those with diabetes, require careful monitoring and management of blood glucose levels to avoid compromising image quality. In cases of hyperglycemia, achieving an euglycemic state is recommended before proceeding with imaging.

Imaging Environment: The environment in which the patient undergoes imaging must be quiet and dimly lit, with minimal interaction to prevent unintended alterations in cerebral metabolism. The patient should remain awake with their eyes open, as closing the eyes can decrease metabolism in the occipital cortex, which could be relevant for specific clinical indications like DLB.

Acquisition and Analysis: The guidelines recommend both static and dynamic image acquisitions depending on the clinical question. Static images should generally be acquired 30 to 40 minutes post-injection of [18F]FDG to assess neuronal activity. However, for neuro-oncological purposes, a delayed scan might be more appropriate. Advanced image analysis methods, including semiquantitative and voxel-based approaches, are highlighted as crucial for improving the detection of subtle metabolic changes. These methods help identify hypometabolic patterns that correspond with specific neurodegenerative conditions.

Dynamic imaging can be used for more complex cases or when advanced quantitative data is needed. This involves capturing multiple sequential sets of images from the time of radiotracer administration. Semiquantitative analysis, aided by automated software tools, allows clinicians to pinpoint abnormalities more accurately and enhances diagnostic confidence.

The updated SNMMI and EANM guidelines for [^{18}F]FDG PET brain imaging provide a comprehensive framework for clinicians to standardise procedures and improve diagnostic accuracy. With advances in PET technology, including digital PET and hybrid PET/MR systems, coupled with refined best practices in patient preparation and image acquisition, practitioners can make more precise diagnoses of neurological and psychiatric conditions. Adopting these guidelines helps optimise the clinical impact of [^{18}F]FDG PET, ensuring early and accurate detection of brain disorders, improving patient outcomes and enhancing the quality of care in nuclear medicine.

Source: **Journal of Nuclear Medicine**

Image Credit: **iStock**

Published on : Sun, 27 Oct 2024